Sample: Sample solution

- Allow the elution to continue for 20 min, and measure the areas for all the peaks, excluding the peaks of Mobile phase A.
- Calculate the percentage of each impurity in the portion of Brinzolamide taken:

Result =
$$(r_U/r_T) \times 100$$

= peak response for each impurity r_U

 r_{τ} = sum of all the peak responses Acceptance criteria 1: NMT 0.3% for any individual impurity

Analysis 2

Use Mobile phase B.

- Sample: Sample solution Allow the elution to continue for 20 min, and measure the areas for brinzolamide and all the peaks having a relative retention greater than 6.
- Calculate the percentage of each impurity in the portion of Brinzolamide taken:

Result =
$$(r_U/r_T) \times 100$$

= peak response for each impurity r_U

- r_{τ} = sum of all the peak responses Acceptance criteria 2: NMT 0.3% for any individual impurity; NMT 1.0% for total impurities from Analysis 1 and Analysis 2

SPECIFIC TESTS

 Loss on Drying (731) Analysis: Dry under vacuum at 100°–105° for 3 h. Acceptance criteria: NMT 0.5%

ADDITIONAL REQUIREMENTS

- PACKAGING AND STORAGE: Preserve in well-closed containers.
- **USP REFERENCE STANDARDS** $\langle 11 \rangle$ USP Brinzolamide RS
 - USP Brinzolamide Related Compound A RS
 - Brinzolamide (S)-isomer. $C_{12}H_{21}N_3O_5S_3$ 383.52

 - USP Brinzolamide Related Compound B RS (R-4-Amino)-2,3-dihydro-2-(3-methoxypropyl)-4H-thieno
 - [3,2,-e]-thiazine-6-sulfonamide-1,1-dioxide ethandioate 1.1 $C_{10}H_{17}N_{3}O_{5}S_{3}\cdot C_{2}H_{2}O_{4}$ 445.49

Brinzolamide Ophthalmic Suspension

DEFINITION

USP Monographs

Brinzolamide Ophthalmic Suspension is a sterile, aqueous suspension of Brinzolamide containing a suitable antimicrobial preservative. It contains NLT 90.0% and NMT 110.0% of the labeled amount of brinzolamide $(C_{12}H_{21}N_{3}O_{5}S_{3}).$

IDENTIFICATION

A. The retention time of the major peak of the Sample solution corresponds to that of Standard solution A, as obtained in the Assay.

ASSAY

Change to read:

- PROCEDURE
 - 11.75 g/L of ammonium acetate in water. Ad-Buffer: just with acetic acid to a pH of 5.2.

Mobile phase: Methanol and Buffer (35:65) Standard solution A: 0.2 mg/mL of USP Brinzolamide RS in Mobile phase System suitability solution: 0.06 mg/mL of USP Brinzolamide Related Compound B RS in Standard solution Sample solution: Nominally 0.2 mg/mL of brinzolamide in *Mobile phase* prepared as follows. Transfer a volume of Ophthalmic Suspension, equivalent to 10 mg of brinzolamide, into a 50-mL volumetric flask, and dilute with Mobile phase to volume. Chromatographić system (See Chromatography (621), System Suitability.) Mode: LC **Detector:** UV 254 nm **Column:** 4.6-mm × 15-cm; 5-µm packing L1 Flow rate: 1.0 mL/min Injection volume: 20 µL System suitability Samples: Standard solution A and System suitability solution [NOTE—The relative retention times for brinzolamide related compound B are between 0.48 and 0.61, and the relative retention time for brinzolamide is 1.0.] Suitability requirements **Resolution:** NLT 4.5 between the brinzolamide and brinzolamide related compound B peaks, *System suit*ability solution **Tailing factor:** NMT 2.0, System suitability solution Relative standard deviation: NMT 2.0%, Standard solution A Analysis Samples: Standard solution A and Sample solution Calculate the percentage of the labeled amount of brinzolamide $(C_{12}H_{21}N_3O_5S_3)$ in the portion of Ophthalmic Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

- = peak response from the Sample solution r_U
- = peak response from *Standard* solution A = concentration of USP Brinzolamide RS in rs Cs Standard solution A (mg/mL)
- = nominal concentration of brinzolamide in the Cu Sample solution (mg/mL)
- Acceptance criteria: 90.0%–110.0%

IMPURITIES

Change to read:

LIMIT OF BRINZOLAMIDE RELATED COMPOUND A Mobile phase: Dehydrated alcohol, Achromatographic hexane, *LUSP38* methanol, and diethylamine (55: 40: 5: 0.2) System suitability solution: 0.4 mg/mL of USP Brinzolamide RS and 0.02 mg/mL of USP Brinzolamide Related Compound A RS in dehydrated alcohol Sample solution: Transfer a volume of Ophthalmic Suspension, equivalent to 10 mg of brinzolamide, to a 25-mL volumetric flask. Dilute with alcohol to volume. Chromatographic system (See Chromatography (621), System Suitability.) Mode: LC Detector: UV 254 nm Column: 4.6-mm × 25-cm; packing L51 Flow rate: 0.75 mL/min **Injection volume:** 5 µL System suitability Sample: System suitability solution [NOTE—The relative retention times for brinzolamide and brinzolamide related compound A are 1.0 and

Suitability requirements

- **Resolution:** NLT 1.8 between the brinzolamide and brinzolamide related compound A peaks
- Column efficiency: NLT 2000 theoretical plates for the brinzolamide peak
- Tailing factor: NMT 1.8 for the brinzolamide peak Analysis
- **Sample:** Sample solution
- Calculate the percentage of brinzolamide related com-pound A in the portion of Ophthalmic Suspension taken:

Result =
$$(r_U/r_T) \times 100$$

- = peak response for brinzolamide related ru compound A
- **r**_T = sum of the peak responses for brinzolamide and brinzolamide related compound A Acceptance criteria: NMT 1.5%
- **ORGANIC IMPURITIES**
 - Buffer, Mobile phase, Standard solution A, System suitability solution, Sample solution, Chromato-graphic system, and System suitability: Proceed as
 - directed in the Assay. Standard solution B: 2.5 μg/mL of USP Brinzolamide Related Compound B RS in Mobile phase

Analysis

Samples: Sample solution and Standard solution B Calculate the percentage of each impurity in the portion of Ophthalmic Suspension taken:

 $\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$

- r_U = peak response for each impurity from the Sample solution
- = peak response for brinzolamide related rs compound B from *Standard solution B* = concentration of USP Brinzolamide Related
- Cs Compound B RS in Standard solution B (mg/mL)
- = nominal concentration of brinzolamide in the Cu Sample solution (mg/mL)
- M_{r1} = molecular weight of des-ethyl brinzolamide, 356.46
- = molecular weight of des-ethyl brinzolamide M_{r2} oxalate, 445.49

Acceptance criteria

Any individual impurity: NMT 0.5% Total impurities: NMT 2.0%

SPECIFIC TESTS

- **STERILITY TESTS** $\langle 71 \rangle$: It meets the requirements when tested as directed for Test for Sterility of the Product to Be Examined, Membrane Filtration.
- **PH** (**791**): 6.5–8.5


ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers. Store at a temperature between 4° and 30°.
- **USP REFERENCE STANDARDS** $\langle 11 \rangle$ USP Brinzolamide RS USP Brinzolamide Related Compound A RS Brinzolamide (S)-isomer. $C_{12}H_{21}N_3O_5S_3$ 383.52

Μ

- USP Brinzolamide Related Compound B RS
- (R-4-Amino)-2,3-dihydro-2-(3-methoxypropyl)-4H-thieno [3,2,-e]-thiazine-6-sulfonamide-1,1-dioxide ethandioate
- $C_{10}H_{17}N_3O_5S_3 \cdot C_2H_2O_4$ 445.49

Bromocriptine Mesylate



- $C_{32}H_{40}BrN_5O_5 \cdot CH_4SO_3$ Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5' α)-;
- 2-Bromoergocryptine monomethanesulfonate (salt) [22260-51-1].

DEFINITION

Bromocriptine Mesylate contains NLT 98.0% and NMT 102.0% of $C_{32}H_{40}BrN_5O_5 \cdot CH_4SO_3$, calculated on the dried basis.

IDENTIFICATION

- A. INFRARED ABSORPTION (197M): Undried
 - **B. ULTRAVIOLET ABSORPTION** $\langle 1970 \rangle$ Sample solution: 50 µg/mL in 0.1 M methanolic methanesulfonic acid

Acceptance criteria: Meets the requirements

ASSAY

PROCEDURE

- Sample solution: 600 mg of Bromocriptine Mesylate Analysis: Dissolve with 80 mL of a mixture of acetic an-hydride and glacial acetic acid (7:1). Titrate with 0.1 N perchloric acid VS. Perform a blank determination, and make any necessary correction (see *Titrimetry* (541)). Each mL of 0.1 N perchloric acid is equivalent to 75.07 mg of C₃₂H₄₀BrN₅O₅ · CH₄SO₃.
- Acceptance criteria: 98.0%–102.0% on the dried basis

IMPURITIES

Inorganic Impurities • Residue on Ignition (281): NMT 0.1%

Delete the following:

• HEAVY METALS, Method II (231): NMT 20 ppm (Official 1-Dec-2015)

Organic Impurities

- PROCEDURE 1: LIMIT OF METHANESULFONIC ACID CONTENT Sample solution: 400 mg of Bromocriptine Mesylate Analysis: Dissolve with 70 mL of methanol. Titrate under nitrogen with 0.1 N methanolic potassium hydroxide VS. Perform a blank determination, and make any necessary correction (see Titrimetry (541)). Each mL of 0.1 N methanolic potassium hydroxide is equivalent to 9.61 mg of CH₃SO₃H.
 - Acceptance criteria: NLT 12.5% and NMT 13.4% of CH₃SO₃H on the dried basis
- PROCEDURE 2
 - **Solution A:** 0.1 N citric acid solution. Adjust with hydrochloric acid to a pH of 2.0.
 - Diluent: Methanol and Solution A (1:1)
 - Solution B: Acetonitrile and 0.01 M phosphate buffer,
 - Solution C: Acetonitrile and 0.01 M phosphate buffer, pH 7.0 (2:3)
 - Mobile phase: See the gradient table below.

USP Monographs